ARS Pharmaceuticals is spending $72.2 million per quarter to sell a product generating $17.5 million in U.S. net product revenue — a 4-to-1 burn ratio that defines exactly how much the CVS Caremark formulary decision in early June matters. Without that coverage win, the math on neffy’s commercial trajectory stays punishing regardless of how many schools adopt the product or how many prescribers have written at least one script.
The strategic logic here is front-loaded investment ahead of a coverage inflection. ARS expanded its salesforce from 106 to 148 representatives this quarter, funded through internal reallocation rather than new capital, and more than 28,000 providers have now prescribed neffy — but roughly half are one-and-done prescribers, which signals awareness without habit. Renewal volume is expected to layer in during the second half of 2026, and the FDA’s removal of the age restriction for the 1 mg dose in late March expands the addressable population to all patients weighing 33 lbs or more. That label cleanup was necessary housekeeping. It is not a demand catalyst on its own.
The CVS Caremark proposal is described as being in “final stages of approval” with economics sitting within ARS’s long-term gross-to-net retention target of roughly 50 percent. That retention figure is the real variable. At 50 percent gross-to-net on a $199 point-of-sale cash price fallback and an expanding Medicaid footprint — nine unrestricted state formularies now, a majority targeted by early 2027 — the unit economics become defensible, but only if volume scales fast enough to outrun the $201 million cash runway. Management believes that runway reaches cash-flow break-even, but a net quarterly loss of $60.6 million leaves very little margin for a formulary miss or a slower-than-expected renewal ramp.
The single marker that determines whether this quarter reads as an inflection or a warning sign: the CVS Caremark decision in early June. A formulary addition without prior authorization would functionally convert neffy from a specialty product requiring active physician effort into a default option at the pharmacy counter — and that structural shift, not salesforce size or school programs, is what closes the gap between $17.5 million quarters and break-even.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
